Viz.ai is the leader in building and deploying AI-powered Care Pathways and helping doctors do their work. The Viz Platform is deployed in 2,000 hospitals across the United States and trusted by many of the leading life sciences companies. The platform uniquely combines real-time, multimodal clinical data with deep clinician engagement to detect disease earlier, coordinate care teams, and help ensure patients receive the right treatment faster. Viz.ai was the first company to be awarded CMS reimbursement for AI and is ranked the #1 Healthcare AI Platform by hospitals and health systems in the Black Book Research survey. For more information, visit Viz.ai.
Freenome is a personalized cancer detection company using an AI-driven multiomics platform to develop and optimize single- and multi-cancer blood tests that can identify cancer in its earliest, most treatable stages.
We operate an expansive, CLIA-certified clinical and research lab in our headquarters in Brisbane, CA. Our development of SimpleScreen CRC (approved by the FDA in July 2026) for colorectal cancer screening, SimpleScreen Lung (launched as a laboratory-developed test in October 2026) and a pipeline of tests for additional indications is designed to increase cancer screening participation among millions of at-risk individuals.
Freenome went public in July 2026, entering Nasdaq under the ticker symbol “FRNM” and raising gross proceeds of $310 million. The company has a licensing agreement with Abbott to lead the U.S. commercialization of SimpleScreen CRC, as well as a strategic collaboration partnership with Roche for R&D and ex-U.S. commercialization of our screening technology.
A ‘Freenomer’ is a mission-driven employee who is fueled by the opportunity to make a positive impact on patients' lives, who thrives in a culture of respect and cross-functional collaboration, and whose work makes a significant impact on the company and their career.
Lunit is a leading provider of AI solutions for cancer diagnostics and therapeutics, with a mission to conquer cancer through AI.
Our clinically proven AI enables healthcare providers to detect cancer earlier, make more precise treatment decisions, and improve patient outcomes — transforming how cancer is diagnosed and treated.
Our technology spans the entire cancer continuum, from risk prediction and screening optimization to early detection and precision oncology.
Lunit’s breast and chest imaging AI boosts diagnostic accuracy and efficiency, while our pathology AI is leveraged by leading pharmaceutical companies to drive biomarker discovery and companion diagnostics (CDx) development.
Trusted by 10,000+ sites across 65+ countries,
Lunit continues to redefine global standards in data-driven cancer care.
Learn more about our technology and mission at www.lunit.io/en